pharmaphorum October 15, 2024
Neuroscience specialist Lundbeck has agreed to buy Longboard Pharmaceuticals for $2.6 billion, expanding its pipeline with an epilepsy drug tipped as a future blockbuster.
The Danish drugmaker has offered $60 per share for California biotech Longboard, with the main asset in the deal bexicaserin, an oral, centrally acting serotonin 5-HT 2C receptor super-agonist in late-stage testing for seizures associated with rare forms of epilepsy.
“This transformative transaction will become a cornerstone in Lundbeck’s neuro-rare franchise, with a potential to drive growth into the next decade,” said Charl van Zyl, Lundbeck’s recently appointed chief executive.
It’s the largest acquisition for Lundbeck in recent years, overtaking its $1.95 billion takeover of migraine drug developer Alder BioPharma in 2019, and the first major...
Today's Sponsors
Today's Sponsor